Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 Infection and COVID-19 in Children

Alpana Waghmare, MD\(^a,b\), Diego R. Hijano, MD, MSc\(^c\)*

KEYWORDS
- COVID-19 • Pediatrics • SARS-CoV-2 • Children • MIS-C

KEY POINTS
- Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) prevalence is high in pediatric populations, especially during the Omicron variant and subvariant waves.
- Clinical manifestations of coronavirus disease 2019 (COVID-19) are generally less severe than in adults, although severe disease can occur in high-risk individuals.
- Multisystem inflammatory syndrome in children is a unique post-COVID phenomenon that occurs rarely, mostly in children approximately 1 month after acute SARS-CoV-2 infection.
- SARS-CoV-2 vaccination remains crucial to prevent severe disease in children.
- Treatment considerations generally follow recommendations for adults and older adolescents should be managed similarly to adults.

EPIDEMIOLOGY

Several databases are available to determine the burden of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in pediatric populations. The COVerAGE database (COVerAGE-DB), an open-access database from more than 103 countries, recorded 56.9 million COVID-19 cases children and adolescents aged less than 20 years with a prevalence range from 0% to 37% of the national caseload across countries.\(^1\) Of these, 63% occurred among adolescents aged 10 to 19 years, and 37% occurred among children aged 0 to 9 years. The Pediatric COVID-19 case registry, the largest registry in the United States, collected information from 12,917 children with COVID-19 during the first year of the pandemic.\(^2\) Infections were most common among those 12 to 18 years of age (31%), followed by 5 to 11 years of age (24%) with no significant difference in gender. Most cases were in White Caucasians followed by in Blacks. One in 4 cases was in Hispanic/Latinos. Reported COVID-19 cases in children increased significantly in 2022 during the Omicron surge. In the United States alone, more than 5 million of a total 13 million cases were diagnosed between January 1, 2022 and May 12, 2022, and the percent of total cases occurring in children increased from 10% to 30%.\(^3\) As of February 2022, almost 75% of children and adolescents had serologic evidence of previous infection with SARS-CoV-2, with approximately one-third becoming newly seropositive since December 2021 with the highest in the age group with lowest vaccination rates (5–11 years, 28%).\(^5\)

Most children seem to have asymptomatic, mild, or moderate disease and recover within 1 to 2 weeks of disease onset.\(^7\) However, children with COVID-19 may develop severe complications, such as respiratory distress syndrome, myocarditis, acute renal failure, and multisystem organ failure.\(^10\) Around 0.1% to 1.5% of pediatric COVID-19 patients require hospitalization, representing close to 5% of all pediatric hospitalizations in the United States.\(^3\) Age, race,
and ethnicity have been described as risk factors for hospitalization with the highest rates seen in those aged younger than 12 months, Hispanics, and non-Hispanic Black children.\textsuperscript{15–20} The annual COVID-19-associated hospitalization rate by age is shown in Table 1. Among children hospitalized with COVID-19 in the United States, between 28% and 40% required intensive care unit (ICU), 6% to 18% needed invasive mechanical ventilation, and up to 3% died.\textsuperscript{21,22}

SARS-CoV-2-related death in children and adolescents is rare.\textsuperscript{23,24} On February 2021, a pooled analysis from Europe and the US estimated COVID-19-associated death in children to be 0.17 per 100,000.\textsuperscript{4,25} Among the 4.4 million COVID-19 deaths reported in the COVerAGE-DB, more than 17,200 (0.4%) occurred in children and adolescents aged younger than 20 years, with 53% among adolescents aged 10–19 years, and 47% among children aged 0–9 years.\textsuperscript{1} Case fatality ratios (CFRs) have varied among continents over time. Although Asia had the highest CFR initially, Europe, and North America, followed by South America surpassed those of Asia shortly after a pandemic was declared. High-income countries had an exponential increase in their CFRs compared with low-income countries probably due to underreporting and lower testing capacities from low-income countries.\textsuperscript{26} Specifically, the percentage of COVID-19 mortality in those aged younger than 20 years, varied among countries based on income: high-income (0.1), upper-middle-income (0.6%), low-middle-income (1.2%), and low-income (0.9%) countries.\textsuperscript{1} Cumulative mortality rates for the United States are shown in Table 1.

**RISK FACTORS FOR SEVERE DISEASE**

Our understanding of COVID-19 severity in children has evolved over time. Although children with certain underlying medical conditions are at increased risk for severe illness (hospitalization, need for intensive care or mechanical ventilation, death) evidence associating specific conditions is limited. In addition, children without comorbidities can also experience severe COVID-19.\textsuperscript{11,15,17,18,27–32}

In children aged younger than 2 years, chronic lung disease, neurological disorders, cardiovascular disease, prematurity, or airway abnormalities are associated with an increased risk for severe COVID-19.\textsuperscript{33} Among children aged 2 to 18 years, obesity, diabetes, and feeding tube dependence carried significant risk for severity (Box 1). Individuals with sickle cell disease, due to underlying cardiopulmonary comorbidities, are more likely to be hospitalized, develop pneumonia, and present with hypoxemia due to COVID-19. However, mortality has not been significantly different across studies.\textsuperscript{34–37}

There are conflicting reports on whether immunocompromised individuals, including recipients of solid organ or hematopoietic cell transplants, are at higher risk for severe diseases.\textsuperscript{38–45} Although some of these differences have been adjudicated to lower threshold for hospital admission in children with these conditions, Mukkada and colleagues\textsuperscript{43} showed that cancer is independently associated with severe disease. In their cohort, one-fifth of children and adolescents with cancer experience severe COVID-19, and deaths occurred in a higher proportion than is reported for those without comorbidities. Specifically, in patients aged 15 to 18 years, severe lymphopenia and intensive chemotherapy were independently associated with disease severity.\textsuperscript{43}

Lack of vaccination is the most important modifiable risk factor for severe disease. Among 400 children hospitalized for COVID-19 during the Omicron wave, 9 in 10 were unvaccinated.\textsuperscript{46} COVID-19-associated hospitalization rates among unvaccinated children aged 5 to 11 years were twice as high as rates in children vaccinated with a primary series (19 vs 9 per 100,000).\textsuperscript{46} Similar results have been reported for those aged 12 to

| Age          | Annual Hospitalization Rate per 100,000\textsuperscript{6,133} | Overall Cumulative Mortality per Million\textsuperscript{134} |
|--------------|---------------------------------------------------------------|-------------------------------------------------------------|
| Overall (<18 y) | 48.2                                                          | 18.4\textsuperscript{a}                                      |
| 0–4 y       | 66.8                                                           | <12 mon: 80.6                                               |
| 5–11 y      | 25                                                             | 1–4 y: 9.1                                                  |
| 12–17 y     | 59.9                                                           | 17.8                                                       |
| 18–19 y     | 48.5                                                           |                                                             |

\textsuperscript{a} Range 0–19 y.
17 years, in whom the rates of hospitalization among unvaccinated were 2.5 times higher when compared with vaccinated teens.47 This data is further supported by studies from adults showing the impact of vaccination in preventing severe disease, hospitalization, and death.

CLINICAL MANIFESTATIONS

The clinical presentation of COVID-19 in children is diverse and varies by age. Asymptomatic infection in children ranges from 10% to 42%.8 The most common symptoms in children are fever and cough, followed by shortness of breath, sore throat, headache, myalgia, fatigue, and, less frequently, rhinorrhea.38,48–50 Studies limited to infants have shown that poor feeding with fever in the absence of obvious signs can be part of the clinical presentation. In addition, several groups have described SARS-CoV-2-associated bronchiolitis.51 There is less evidence on the clinical presentation of COVID-19 in immunocompromised children. The Pediatric COVID-19 case registry has 614 immunocompromised patients and 12,309 immunocompetent children.2 Asymptomatic infection was seen in almost 40% of immunocompromised children compared with around 20% in immunocompetent children (Table 2).

Box 1
Risk factors for severe coronavirus disease 2019

disease in children

| Risk factors                                      |
|--------------------------------------------------|
| Asthma or other chronic pulmonary diseases       |
| Obesitya                                         |
| Diabetes mellitus                                |
| Congenital heart disease/cardiovascular disease  |
| Sickle cell disease                               |
| Neurologic conditions                             |
| Metabolic conditions                              |
| Genetic conditions                                |
| Medical complexity                                |
| Immunosuppression                                 |

aBody mass index [BMI] greater than 95th percentile for age and sex.

In an international registry of 1500 children with cancer, asymptomatic infection was reported in one-third, with fever and cough being the most common symptoms in those who became sick.43

Rhinorrhea and stuffy nose and gastrointestinal (GI) symptoms were reported in 10% of cases and tachypnea, sore throat, body aches, and headaches in 5% to 7%. Anosmia, ageusia, chills, and cutaneous manifestations were seen in less than 3% of the patients. Similar results have been reported by others.40–44,52

SARS-CoV-2 produces heterogeneous respiratory involvement in children. The vast majority has mild upper respiratory tract symptoms. However, progression to the lower respiratory tract has been well described, with pneumonia being the most frequent manifestations and acute respiratory distress syndrome the most severe one.27,49,53,54

Chest radiograph imaging is the first preferred method to assess children with suspected pneumonia. Radiologic abnormalities can be present in about half of the patients with dyspnea and differ from that observed in adults. They can be unilateral or bilateral, single, or multiple, and most seen in the lower lobes. Unilateral increased density and bilateral peribronchial changes are commonly seen. Ground-glass opacities and patchy shadowing on a chest computerized tomography (CT) scan are the most recognized signs in children.55–64 Less common manifestations including single-round consolidation, pleural effusion, small nodules, or lymphadenopathy have been reported. According to the US COVID-19 pediatric registry, abnormal findings on pulmonary imaging, (Table 3) during the first week of disease were most seen in immunocompromised children, with the most common radiologic findings being multifocal or patchy opacities, followed by interstitial infiltrates and bronchial thickening.2

Although COVID-19 affects mainly the lungs, extrapulmonary manifestations affecting several systems have been described in adults as well as in children. Myocarditis, pericarditis, heart failure, and arrhythmias have been described in children and adolescents.65 The risk of myocarditis and myocarditis or pericarditis associated with SARS-CoV-2 infection varies by age and gender but is overall low and higher than after mRNA vaccination. The highest incidence is seen in boys aged 12 to 17 years (50.1–64.9 cases per 100,000) followed by boys 5 to 11 years (12.6–17.6 cases per 100,000).66–68 Cardiac manifestations in children with preexisting heart conditions do not significantly differ from those without cardiac disease; however, SARS-CoV-2 can worsen the basal status of this population.69

Neurological manifestations are frequent and vary in severity. Between 20% and 40% of children hospitalized with COVID-19 had one or more neurological symptom, affecting the central and/or peripheral nervous system.70–72 As with cardiac
manifestations, CNS involvement can be seen in the acute phase or as part of multisystem inflammatory syndrome in children (MIS-C). The vast majority of these are transient and fully resolve over time. In addition to anosmia and ageusia, common manifestations are headache, encephalopathy, seizures, and weakness. Children with preexisting neurological disease could experience exacerbation and/or progression of their underlying condition, especially those with neuromuscular disease.

Dermatologic manifestations include the vasculitic chilblain-like acral pattern of the distal toes, consisting of reddish-purple nodules on the distal digits and often refer as “COVID toes” and have been described more frequently in children and young adults. The most common GI symptoms in children with COVID-19 are vomiting and diarrhea, followed by anorexia, abdominal pain, and poor appetite. GI symptoms can be the first manifestation of COVID-19 and can occur with or without respiratory symptoms. Although most of these are self-limited, a Spanish multicenter study showed that children with COVID-19 and GI symptoms had more severe disease than those without GI symptoms. Of note, children with GI symptoms required careful monitoring given that vomiting, abdominal pain, and/or diarrhea can be a manifestation of MIS-C.

**MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN**

MIS-C has been most frequently described in children aged from 1 to 14 years and is most prevalent in children aged older than 5 years. Since first reported in England in April 2020, several studies have reported cases of MIS-C with peaks that lag the peak of acute COVID-19. These have led to a greater understanding of the disease.

| Symptoms                          | General Pediatric, n = 12309 | Immunocompromised, n = 614 |
|-----------------------------------|------------------------------|-----------------------------|
| Fever                             | 9554                         | 383                         | 62.38%                             |
| Cough                             | 2670                         | 229                         | 37.30%                             |
| Rhinorrhea                        | 5362                         | 227                         | 36.97%                             |
| Headache                          | 4590                         | 186                         | 30.29%                             |
| Sore throat                       | 2983                         | 105                         | 17.10%                             |
| Decreased oral intake             | 2584                         | 74                          | 12.05%                             |
| Myalgia                           | 2232                         | 48                          | 7.82%                              |
| Vomiting                          | 1784                         | 74                          | 12.05%                             |
| Lethargy                          | 1612                         | 61                          | 9.93%                              |
| Shortness of breath               | 1528                         | 61                          | 9.93%                              |
| Diarrhea                          | 1346                         | 56                          | 9.12%                              |
| Abdominal pain                    | 1239                         | 71                          | 11.56%                             |
| Nausea                            | 1181                         | 66                          | 10.75%                             |
| Loss of smell/taste               | 1167                         | 49                          | 7.98%                              |
| Constipation                      | 1082                         | 55                          | 8.96%                              |
| Chest pain                        | 958                          | 35                          | 5.70%                              |
| Rash                              | 558                          | 27                          | 4.40%                              |
| Conjunctivitis                    | 472                          | 6                           | 0.98%                              |
| Wheezing                          | 337                          | 6                           | 0.98%                              |
| Seizure                           | 259                          | 8                           | 1.30%                              |
| Apnea                             | 172                          | 5                           | 0.81%                              |
| Hypothermia                       | 54                           | 1                           | 0.16%                              |
| Hemoptysis                        | 32                           | 4                           | 0.65%                              |
| Data from Pediatric COVID-19 Case Registry. Accessed June 28th, 2022. https://www.pedscovid19registry.com.

Waghmare & Hijano
to the hypothesis that MIS-C is an immune-
mediated port infectious complication of SARS-
CoV-2. The incidence of MIS-C early in the
pandemic was 1 case per 3000 infections in individ-
uals aged younger than 21 years. To date, more
than 8525 cases and 69 deaths have been reported
in the United States. The median age of patients
with MIS-C was 9 years. Half of children with
MIS-C were aged between 5 and 13 years and
61% were boys. Almost 60% of the reported pa-
tients with race/ethnicity information available
(N = 8038) occurred in children who are Hispanic/
Latino or Black, non-Hispanic. MIS-C shares charac-
teristics with Kawasaki disease (KD); however, MIS-C affects older children
and disproportionally affects Black and Hispanic
with very few cases described in Asian children.
In addition, GI symptoms are more common and
prominent in MIS-C, and inflammatory markers
tend to be higher when compared with KD. Although these distinctions can be helpful, ulti-
mately, a previous history of SARS-CoV-2 infection
or known COVID-exposure will aid in determining
MIS-C or KD. Although the course of MIS-C
can be severe, requiring intensive care support,
outcomes are overall good with most children
recovering. However, deaths have been reported,
and long-term outcomes in those who have recov-
ered have not been properly studied.

### Post-COVID Conditions

The phenomenon of persistent symptoms
following COVID-19 has been variably termed
long COVID, long-haul COVID, postacute
sequelae of COVID-19, post-COVID, and COVID
syndrome. The WHO defines post-COVID-19 con-
ditions as occurring in individuals with a history of probable or confirmed SARS-CoV-2 infection,
usually 3 months from the onset of COVID-19
with symptoms and that last for at least 2 months

---

**Table 3**

Pulmonary findings during the first week of diagnosis with coronavirus disease 2019 in immunocompetent and immunocompromised children in the US COVID-19 pediatric registry

| Finding                                      | General Pediatric, n = 12309 | Immunocompromised, n = 614 |
|----------------------------------------------|------------------------------|---------------------------|
| Abnormal XR                                  | 911                          | 82                        |
| Abnormal CT                                  | 82                           | 21                        |
| Bronchial or peribronchial thickening/cuffing| 270                          | 10                        |
| Interstitial infiltrates                      | 188                          | 14                        |
| Lobar consolidation                          | 86                           | 10                        |
| Multifocal or patchy opacity                 | 456                          | 52                        |
| Multifocal or patchy opacity or ground glass opacity | 53                   | 12                        |
| Nodule(s)                                    | 9                            | 4                         |
| Tree-in-bud opacities                        | 1                            | 0                         |

Data from Pediatric COVID-19 Case Registry. Accessed June 28th, 2022. https://www.pedscovid19registry.com.
and cannot be explained by an alternative diagnosis.\textsuperscript{102} Importantly, the WHO specifies that a separate definition may be applicable to children. The CDC definition of post-COVID-19 conditions includes a wide range of health consequences that are present 4 or more weeks after infection with SARS-CoV-2.\textsuperscript{101} Overall, post-COVID-19 conditions in children seem to be less common than in adults. An early publication from a national survey in the United Kingdom estimates that 7% to 8% of children may experience continued symptoms for over 12 weeks. The most common symptoms are fatigue, headache, insomnia, trouble concentrating, muscle and joint pain, and cough and can occurred after infection, irrespective of its severity, or MIS-C. These symptoms can limit physical activity, cause distress about symptoms, decrease school attendance/participation, and become mental health challenges.\textsuperscript{102,103} A systematic review of 21 studies that included children and adolescents found a 25.24% prevalence of long-COVID, with mood symptoms, fatigue, and sleep disorders most commonly reported.\textsuperscript{104} Other studies have reported varying ranges of persistent symptoms after COVID. A Danish study reported higher rates of symptoms at 2 months postinfection in children aged 0 to 14 years compared with controls in a cross-sectional case-control study,\textsuperscript{105} whereas an international study of ~1800 children demonstrated very low prevalence of symptoms at day 90.\textsuperscript{106} Several factors may influence the reported prevalence of prolonged symptoms in children and the apparent discrepancy among various studies. Namely, stratification by age, gender, vaccination status, and viral variant are likely needed to fully characterize the effect. Initial data has suggested that the risk of long COVID is reduced in individuals that had received 2 doses of vaccine\textsuperscript{107,108}, however, data specific to children and with newer variants are currently lacking. Infection with different viral variants, especially Omicron, is likely to influence the risk of long COVID\textsuperscript{109}, however, data in children are not yet available.

**Treatment**

Systematic data on the use of specific treatments for COVID-19 in pediatric patients remain limited. Through some clinical trials of COVID-19 therapeutics allowed inclusion of adolescents, adolescent enrollment in most trials was low and sometimes nonexistent. Nonetheless, several agents are now approved and/or have emergency use authorization for use in children and adolescents. As the landscape of therapeutics continues to change and new data become available, recommendations are likely to also change. Guidelines from the Infectious Diseases Society of America (https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/) and the National Institutes of Health (https://www.covid19treatmentguidelines.nih.gov/) are updated regularly and provide up-to-date reviews of currently available data.

**Remdesivir**

Remdesivir is approved by the FDA for use in hospitalized and nonhospitalized pediatric patients aged 28 days or older and weighing 3.0 kg or greater.\textsuperscript{110} Remdesivir for use in early infection was evaluated in nonhospitalized, high-risk adults with mild-to-moderate disease, where a 3-day infusion was associated with an 87% risk reduction of hospitalization or death.\textsuperscript{111} Only 8 adolescents aged younger than 18 years were included in the trial; however, current guidelines recommend consideration of use in nonhospitalized children or hospitalized children not on oxygen, aged 12 years or older who are at high risk of progression to severe COVID-19.\textsuperscript{112} Children aged younger than 12 years can be considered for remdesivir as well, although data are lacking. The efficacy of remdesivir in hospitalized individuals is limited to trials involving adult subjects.\textsuperscript{113-116} Interim results of a phase 2/3, single-arm, open-label study aimed at evaluating the safety, tolerability, and pharmacokinetics of remdesivir in children demonstrated overall acceptable safety profile,\textsuperscript{117} although the lack of a placebo group in this trial limits the evaluation of efficacy. Remdesivir thus is recommended for pediatric patients who have a new or increasing oxygen need.

**Ritonavir-boosted nirmatrelvir (paxlovid)**

The FDA issued an emergency use authorization (EUA) for ritonavir-boosted nirmatrelvir for nonhospitalized individuals with mild to moderate COVID-19 aged ≥12 years and at high risk for progression to severe disease.\textsuperscript{118} Efficacy, however, has only been demonstrated in adults, where an 89% relative risk reduction was found compared to placebo.\textsuperscript{119} Given the efficacy data in adults, ritonavir-boosted nirmatrelvir is recommended for adolescents aged 12 years or older who are at high risk of progressing to severe disease.\textsuperscript{112} Importantly, drug interactions must be considered when administering ritonavir-boosted nirmatrelvir, which may prevent use in certain high-risk populations such as immunocompromised children.

**Monoclonal antibodies**

Several monoclonal antibodies (mAbs) have been developed and received EUAs for adults and children aged 12 years or older; however, emergence
of SARS-CoV-2 variants has rendered most mAbs ineffective for use as treatment. Currently, bebtelovimab is the only mAb available for use that has maintained in vitro activity against Omicron subvariants.\textsuperscript{120} No clinical data is available in either adults or children demonstrating efficacy, thus, despite the EUA for use in nonhospitalized patients, current guidelines do not recommend for or against use in children aged 12 years or older who have mild-to-moderate COVID-19 with high risk of progression to severe COVID-19. Up-to-date guidance on activity of different mAbs against circulating SARS-CoV-2 variants can be found at https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/. The use of mAbs for prophylaxis is discussed below.

**Corticosteroids and other immunomodulators**

In general, despite lack of systematic data on use, recommendations for corticosteroid use in children with COVID-19 follow recommendations in adults. The benefits of corticosteroids have been demonstrated in several clinical trials, including the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial where a mortality benefit was observed in adults with COVID-19 on supplemental oxygen receiving dexamethasone.\textsuperscript{121} Given overall lower mortality in children, and that the strongest effect was seen in patients on higher levels of oxygen support, dexamethasone is reserved for children requiring high flow or more supplemental oxygen.\textsuperscript{112} Several other immunomodulators have been evaluated in adults with moderate to severe COVID-19, including baricitinib, tofacitinib, and tocilizumab.\textsuperscript{122–127} Without pediatric efficacy data, potential benefits of these therapies must be extrapolated from adult studies, and therefore, the use is limited to patients with severe COVID-19 (noninvasive and invasive mechanical ventilation).\textsuperscript{112}

**Prevention and Prophylaxis**

**Vaccination**

The mainstay of prevention of severe COVID-19 in children is vaccination. Currently 2 mRNA vaccines (Pfizer/BioNTech, Moderna) and 1 protein subunit vaccine (Novavax) are either approved or hold EUA status for children in the United States. Both the Pfizer-BioNTech and Moderna vaccines are authorized down to 6 months of age, whereas the Novavax vaccine is authorized down to 12 years of age. Up to date dosing schedules for primary series and booster doses can be found at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html#recommendations. Vaccine effectiveness estimates for children have varied by vaccine dosing regimens, history of prior infection, and SARS-CoV-2 variant predominance;\textsuperscript{128} however, protection against severe disease remains an important clinical endpoint. The American Academy of Pediatrics and the Advisory Committee on Immunization Practices recommend vaccination (including booster doses) for all children aged 6 months or older.\textsuperscript{129,130}

**Monoclonal antibodies for preexposure and postexposure prophylaxis**

As outlined above, emergence of SARS-CoV-2 variants has resulted in several mAbs being no longer effective for both treatment and prophylaxis. Prophylaxis with mAb is generally reserved for those that are unable to mount an adequate response to vaccination, namely individuals that are moderately to severely immunocompromised. Tixagevimab 300 mg plus cilgavimab 300 mg (Evusheld) is the only available mAb combination currently available for use as preexposure prophylaxis against SARS-CoV-2 for adults and adolescents aged 12 years or older with moderate-to-severe immunocompromise or in individuals unable to be fully vaccinated due to history of severe adverse reactions to COVID vaccines.\textsuperscript{112} Of note, current dosing guidance, including repeat dosing at 6 months, are not based on clinical trial data therefore data on efficacy is limited, especially in pediatrics.\textsuperscript{131,132} No mAbs are currently approved for postexposure prophylaxis; however, this may change as new variants and mAbs emerge.

**SUMMARY**

Although our knowledge of COVID-19 has significantly evolved over the course of the pandemic, COVID-19 continues to be an important health problem around the world. We have a better understanding of the various clinical presentations and risks factors for severe disease. We have access to accurate diagnostics tests and limited, yet effective therapies targeting the virus or modulating the immune response to it. Vaccines, which continue to prove safe and effective, are now available for anyone aged 6 month and older. However, lack of access, inequity, disinformation, and vaccine hesitancy have led to disparities in vaccination rates among countries, enabling the virus to mutate and leaving all of us vulnerable to new surges. Particularly vulnerable, are children, who have the lowest vaccination rates and have been increasingly affected with each new wave driven by a different variant of concern. Scientifically we have made remarkable and unprecedented progress and while many answers
lay ahead, we will undoubtedly be able to answer them. However, the biggest questions, is whether we will be able to bring down the social and economic disparities needed to overcome this pandemic.

**CLINICS CARE POINTS**

- Although severe COVID-19 is less frequent in children, the direct and indirect effects of COVID-19 on children’s health continues to be substantial.
- Vaccines against SARS-CoV-2 are available for everyone 6 months of age and older. They have been proven to be safe and effective in reducing the risk of severe disease.

**FINANCIAL DISCLOSURES**

A. Waghmare receives grant support from Ansun Biopharma, Allovir and Pfizer and is an Advisory Board Member for Kyorin Pharmaceutical. D.R. Hijano has no financial disclosures.

**REFERENCES**

1. COVID-19 confirmed cases and deaths. the United Nations Children’s Fund (UNICEF). Available at: https://data.unicef.org/resources/covid-19-confirmed-cases-and-deaths-dashboard/. Accessed June 28th, 2022.
2. Pediatric COVID-19 case registry. Available at: https://www.pedscovid19registry.com. Accessed June 28th, 2022.
3. Children and COVID-19: state-level data report. American Academy of pediatrics. Available at: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. Accessed June 24, 2022.
4. COVID data tracker/demographics. Centers for Disease Control and Prevention. Available at: https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed June 28, 2022.
5. COVID-19 dashboard by the center for systems science and engineering (CSSE) at johns hopkins university (JHU). Johns hopkins university, center for systems science and engineering. 2022. Available at: https://coronavirus.jhu.edu/map.html. Accessed June 28, 2022.
6. Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies - United States, september 2021-february 2022. MMWR Morb Mortal Wkly Rep 2022;71(17):606–8.
7. Badal S, Thapa Bajgian K, Badal S, et al. Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: a systematic review and meta-analysis. J Clin Virol 2021;135:104715.
8. Milani GP, Bottino I, Rocchi A, et al. Frequency of children vs adults carrying severe acute respiratory syndrome coronavirus 2 asymptomatically. JAMA Pediatr 2021;175(2):193–4.
9. Yasuhara J, Kuno T, Takagi H, et al. Clinical characteristics of COVID-19 in children: a systematic review. Pediatr Pulmonol 2020;55(10):2565–75.
10. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145(6). https://doi.org/10.1542/peds.2020-0702.
11. Drouin O, Hepburn CM, Farrar DS, et al. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020. CMAJ 2021;193(38):E1483–93.
12. Forrest CB, Burrows EK, Mejias A, et al. Severity of acute COVID-19 in children <18 Years old march 2020 to december 2021. Pediatrics 2022;149(4). https://doi.org/10.1542/peds.2020-055765.
13. Irfan O, Muttalib F, Tang K, et al. Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. Arch Dis Child 2021;106(5):440–8.
14. Kainth MK, Goenka PK, Williamson KA, et al. Early experience of COVID-19 in a US children's hospital. Pediatrics 2020;146(4). https://doi.org/10.1542/peds.2020-003186.
15. Bellino S, Punzo O, Rota MC, et al. COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics 2020;146(4). https://doi.org/10.1542/peds.2020-009399.
16. Butt AA, Dargham SR, Loka S, et al. COVID-19 disease severity in children infected with the omicron variant. Clin Infect Dis 2022. https://doi.org/10.1093/cid/ciac275.
17. Campbell JI, Dubois MM, Savage TJ, et al. Comorbidities associated with hospitalization and progression among adolescents with symptomatic coronavirus disease 2019. J Pediatr 2022;245:102–10.e2.
18. Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci 2022;37(5):e35.
19. Martin B, DeWitt PE, Russell S, et al. Characteristics, outcomes, and severity risk factors associated with SARS-CoV-2 infection among children in the US National COVID cohort collaborative. JAMA Netw Open 2022;5(2):e2143151. https://doi.org/10.1001/jamanetworkopen.2021.43151.
20. O'Neill L, Chumbler NR. Risk factors for COVID-19 hospitalization in school-age children. Health Serv Res Manag Epidemiol 2022;9. 23333928221104677.
21. American Academy of Pediatrics. Coronaviruses, Including SARS-CoV-2 and MERS-CoV. In:
Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. Itasca, IL: American Academy of Pediatrics. 2021, 280–285.

22. COVID Data Tracker. Centers for disease control and prevention. Available at: https://covid.cdc.gov/covid-data-tracker/?utm_campaign=Private%20Equity%20Newsletter&utm_source=hs_email&utm_medium=email&hsenc=pc2ANqtz-_M9OSt7jgR0ag2vPQVmdjmHOJhtBFAKqsX0SpR1RdsT3Wm9YvOeOxCxLivUaeChn93xxw#cases-deaths-testing-trends. Accessed June 20, 2022.

23. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2: Associated deaths among persons aged <21 Years - United States, February 12-July 31, 2020. MMWR Morb Mortal Wkly Rep 2020;69(37):1324–9.

24. Smith C, Odd D, Harwood R, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med 2022;28(1):185–92.

25. Bhopal SS, Bagaria J, Olabi B, et al. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Health 2021;5(5): e12–3.

26. Abou Ghayda R, Lee KH, Han YJ, et al. The global case fatality rate of coronavirus disease 2019 by continent and national income: a meta-analysis. J Med Virol 2022;94(6):2402–13.

27. Chao JY, Derespina KR, Herold BC, et al. Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a tertiary care medical center in New York city. J Pediatr 2020;223:14–9.e2.

28. Graff K, Smith C, Silveira L, et al. Risk factors for severe COVID-19 in children. Pediatr Infect Dis J 2021;40(4):e137–45.

29. Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 2021;4(6):e211182.

30. Tsabouri S, Makis A, Kosmeri C, et al. Risk factors for severity in children with coronavirus disease 2019: a comprehensive literature review. Pediatr Clin North Am 2021;68(1):321–38.

31. Ward JL, Harwood R, Smith C, et al. Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year. Nat Med 2022;28(1):193–200.

32. Zhou B, Yuan Y, Wang S, et al. Risk profiles of severe illness in children with COVID-19: a meta-analysis of individual patients. Pediatr Res 2021;90(2):347–52.

33. Woodruff RC, Campbell AP, Taylor CA, et al. Risk factors for severe COVID-19 in children. Pediatrics 2021. https://doi.org/10.1542/peds.2021-053418.

34. Heilbronner C, Berteloot L, Tremolieres P, et al. Patients with sickle cell disease and suspected COVID-19 in a paediatric intensive care unit. Br J Haematol 2020;190(1):e21–4.

35. Martin OY, Darbari DS, Margulies S, et al. Pediatric sickle cell disease and the COVID-19 pandemic: a year in review at children’s national hospital. Blood 2021;138(Supplement 1):3036.

36. Sayad B, Karimi M, Rahimi Z. Sickle cell disease and COVID-19: susceptibility and severity. Pediatr Blood Cancer 2021;68(8):e29075.

37. Singh A, Brandow AM, Panepinto JA. COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Adv 2021;5(7):1915–21.

38. Bisogno G, Provenzi M, Zama D, et al. Clinical Characteristics and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italian Pediatric Oncology Patients: a Study From the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. J Pediatr Infect Dis Soc 2020;9(5):530–4.

39. Goss MB, Galván NTN, Ruan W, et al. The pediatric solid organ transplant experience with COVID-19: an initial multi-center, multi-organ case series. Pediatr Transplant 2021;25(3):e13868.

40. Haeusler GM, Ammann RA, Carlesse F, et al. SARS-CoV-2 in children with cancer or after hematopoietic stem cell transplant: an analysis of 131 patients. Eur J Cancer 2021;159:78–86.

41. Kebudi R, Kurucu N, Tuğcu D, et al. COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: a nationwide study. Pediatr Blood Cancer 2021;68(6):e28915.

42. Millen GC, Arnold R, Cazier JB, et al. COVID-19 in children with cancer or after haematopoietic stem cell transplant: an analysis of 131 patients. Eur J Cancer 2021;159:78–86.

43. Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol 2021;22(10):1416–26.

44. Nicastro E, Verdoni L, Bettini LR, et al. COVID-19 in immunosuppressed children. Front Pediatr 2021;9:629240.

45. Rüthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOS-S registry. Ann Hematol 2021;100(2):383–93.

46. Shi DS, Whitaker M, Marks KJ, et al. Hospitalizations of children aged 5-11 Years with laboratory-confirmed COVID-19 - COVID-NET, 14 states, march 2020-february 2022. MMWR Morb Mortal Wkly Rep 2022;71(16):574–81.

47. Havers FP, Whitaker M, Seif JL, et al. Hospitalization of adolescents aged 12-17 Years with
laboratory-confirmed COVID-19 - COVID-NET, 14 states, march 1, 2020-april 24, 2021. MMWR Morb Mortal Wkly Rep 2021;70(23):851–7.

48. Bailey LC, Razzaghi H, Burrows EK, et al. Assessment of 135 794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatr 2021;175(2):176–84.

49. Derespina KR, Kaushik S, Plichta A, et al. Clinical manifestations and outcomes of critically ill children and adolescents with coronavirus disease 2019 in New York city. J Pediatr 2020;226:55–63.

50. Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: a systematic review. Eclinicalmedicine 2020;24:100433.

51. Di Nardo M, van Leeuwen G, Loreti A, et al. A literature review of 2019 novel coronavirus (SARS-CoV2) infection in neonates and children. Pediatr Res 2021;89(5):1101–8.

52. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol Mar 2020;21(3):335–7.

53. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 26 2020;368:m1091.

54. Jurado Hernández JL, Álvarez Orozco IF. COVID-19 in children: respiratory involvement and some differences with the adults. Front Pediatr 2021;9:622240.

55. Li B, Shen J, Li L, et al. Radiographic and clinical features of children with coronavirus disease (COVID-19) pneumonia. Indian Pediatr 2020;57(5):423–6.

56. Nino G, Zember J, Sanchez-Jacob R, et al. Pediatric lung imaging features of COVID-19: a systematic review and meta-analysis. Pediatr Pulmonol 2021;56(1):252–63.

57. Caro-Dominguez P, Shelmerdine SC, Toso S, et al. Thoracic imaging of coronavirus disease 2019 (COVID-19) in children: a series of 91 cases. Pediatr Radiol 2020;50(10):1354–68.

58. Chen Z, Fan H, Cai J, et al. High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages. Eur J Radiol 2020;126:108972.

59. Duan YN, Zhu YQ, Tang LL, et al. CT features of novel coronavirus pneumonia (COVID-19) in children. Eur Radiol 2020;30(8):4427–33.

60. Kurian J, Blumfield E, Levin TL, et al. Imaging findings in acute pediatric coronavirus disease 2019 (COVID-19) pneumonia and multisystem inflammatory syndrome in children (MIS-C). Pediatr Radiol 2022;1–13. https://doi.org/10.1007/s00247-022-05393-9.

61. Li W, Cui H, Li K, et al. Chest computed tomography in children with COVID-19 respiratory infection. Pediatr Radiol 2020;50(6):796–9.

62. Lu Y, Wen H, Rong D, et al. Clinical characteristics and radiological features of children infected with the 2019 novel coronavirus. Clin Radiol 2020;75(7):520–6.

63. Palabiyik F, Kokurcan SO, Hatipoglu N, et al. Imaging of COVID-19 pneumonia in children. Br J Radiol Sep 1 2020;93(1113):20200647.

64. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol 2020;55(5):1169–74.

65. Jone PN, John A, Oster ME, et al. SARS-CoV-2 infection and associated cardiovascular manifestations and complications in children and young adults: a scientific statement from the american heart association. Circulation 2022;145(19):e1037–52.

66. Block JP, Boehmer TK, Forrest CB, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination - PCORnet, United States, january 2021-january 2022. MMWR Morb Mortal Wkly Rep 2022;71(14):517–23.

67. Boehmer TK, Kompaniyets L, Lavry AM, et al. Association between COVID-19 and myocarditis using hospital-based administrative data - United States, march 2020-january 2022. MMWR Morb Mortal Wkly Rep 2021;70(35):1228–32.

68. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, péricarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med 2022;28(2):410–22.

69. Alsaied T, Aboulhosn JA, Cotts TB, et al. Coronavirus disease 2019 (COVID-19) pandemic implications in pediatric and adult congenital heart disease. J Am Heart Assoc 2020;9(12):e017224.

70. Fink EL, Robertson CL, Wainwright MS, et al. Prevalence and risk factors of neurologic manifestations in hospitalized children diagnosed with acute SARS-CoV-2 or MIS-C. Pediatr Neurol 2022;128:33–44.

71. LaRovere KL, Riggs BJ, Poussaint TY, et al. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol 2021;78(5):536–47.

72. Lin JE, Asfour A, Sewell TB, et al. Neurological issues in children with COVID-19. Neurosci Lett 2021;743:135567.

73. Andina D, Belloni-Fortina A, Bodemer C, et al. Skin manifestations of COVID-19 in children: Part 1. Clin Exp Dermatol 2021;46(3):444–50.

74. Assa A, Benninga MA, Borrelli O, et al. Gastrointestinal perspective of coronavirus disease 2019 in
children-an updated review. J Pediatr Gastroenterol Nutr 2021;73(3):299–305.

75. Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology 2020;159(1):81–95.

76. Dipasquale V, Passanisi S, Cucinotta U, et al. Implications of SARS-CoV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease. Ital J Pediatr 2021;47(1):71.

77. Moradveisi B, Ataee P, Ghaffarieh A, et al. Diarrhea as a presenting symptom of coronavirus disease 2019 in children. Adv Biomed Res 2020;9:35.

78. Wang J, Yuan X. Digestive system symptoms and function in children with COVID-19: a meta-analysis. Medicine (Baltimore) 19 2021;100(11): e24897.

79. Gonzalez Jimenez D, Velasco Rodriguez-Belvis M, Ferrer Gonzalez P, et al. COVID-19 gastrointestinal manifestations are independent predictors of PICU admission in hospitalized pediatric patients. Pediatr Infect Dis J 2020;39(12):e459–62.

80. Health department-reported cases of multisystem inflammatory syndrome in children (MIS-C) in the United States. Centers for disease control and prevention. Available at: https://covid.cdc.gov/covid-data-tracker/#mis-national-surveillance. Accessed June 29, 2022.

81. Antuñez-Montes OY, Escamilla MI, Figueroa-Uribe AF, et al. COVID-19 and multisystem inflammatory syndrome in Latin American children: a multinational study. Pediatr Infect Dis J 2021;40(1):e1–6.

82. Belay ED, Abrams J, Oster ME, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr 2021;175(8):837–45.

83. Dufort EM, Kourmans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York state. N Engl J Med 2020;383(4):347–58.

84. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. Children and adolescents. N Engl J Med 2020;383(4):334–46.

85. Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 2021;325(11):1074–87.

86. Miller AD, Zambrano LD, Yousaf AR, et al. Multisystem inflammatory syndrome in children-United States, February 2020-July 2021. Clin Infect Dis 2021. https://doi.org/10.1093/cid/ciab1007.

87. Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open 2021;4(6):e2116420.

88. Sterman B, Abrams JY, Godfred-Cato SE, et al. Racial and ethnic disparities in multisystem inflammatory syndrome in children in the United States, march 2020 to february 2021. Pediatr Infect Dis J 2021;40(11):e400–6.

89. Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C). Center for disease control and prevention. Available at: https://www.cdc.gov/mis/mis-c/hcp/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmis%2Fmsec%2Fhcpc%2Findex.html. Accessed June 27, 2022.

90. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. World Health Organization. Available at: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19. Accessed June 21, 2022.

91. Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York city. JAMA 2020;324(3):294–6.

92. Choi NH, Fremed M, Starc T, et al. MIS-C and cardiovascular abnormalities. Pediatrics 2020;146(6). https://doi.org/10.1542/peds.2020-009738.

93. Sperotto F, Friedman KG, Son MBF, et al. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr 2021;180(2):307–22.

94. Wu EY, Campbell MJ. Cardiac manifestations of multisystem inflammatory syndrome in children (MIS-C) following COVID-19. Curr Cardiol Rep 2021;23(11):168.

95. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395(10239):1771–8.

96. Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020;324(3):259–69.

97. Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory multisystem inflammatory syndrome in children-United States, February 2020-July 2021. Clin Infect Dis 2021. https://doi.org/10.1093/cid/ciab1007.

98. Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr Pulmonol 2021;56(5):837–48.

99. Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr 2021;180(7):2019–34.
100. Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22(4):e102–7.

101. CDC. Post-COVID conditions: overview for healthcare providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. Accessed 8 20, 2022.

102. Zimmermann P, Pittet LF, Curtis N. Long covid in children and adolescents. BMJ Jan 20 2022;376:o143.

103. Zimmermann P, Pittet LF, Curtis N. How common is long COVID in children and adolescents? Pediatr Infect Dis J 2021;40(12):e482–7.

104. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Scientific Rep 2022;12(1):9950.

105. Kikkenborg Berg S, Palm P, Nygaard U, et al. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health 2022;6(9):614–23.

106. Funk AL, Kuppermann N, Florin TA, et al. Post-COVID-19 conditions among children 90 Days after SARS-CoV-2 infection. JAMA Netw Open 2022;5(7):e2223253. https://doi.org/10.1001/jamanetworkopen.2022.23253.

107. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022;22(1):43–55.

108. Kuodi P, Gorelick Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. medRxiv 2022. https://doi.org/10.1101/2022.01.05.22268800.

109. Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022;399(10343):2263–4.

110. Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children. 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children. [Accessed 20 August 2022].

111. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022;386(4):305–15.

112. Panel. C-TG. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov. Accessed August 20, 2022.

113. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 Days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020;324(11):1048–57.

114. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - final report. N Engl J Med 2020;383(19):1813–26.

115. Consortium WHOST. Remdesivir and other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 2022;399(10339):1941–53.

116. Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ 2022;194(7):E242–51.

117. Ahmed A., Rojo P., Agwu A., et al. Remdesivir treatment for COVID-19 in hospitalized children: CARAVAN interim results. 2022. Available at: https://www.croiconference.org/abstract/remdesivir-treatment-for-covid-19-in-hospitalized-children-caravan-interim-results/. Accessed August 20, 2022.

118. Administration. FaD. Fact sheet for healthcare providers: emergency use authorization for Paxlovid.. Available at: https://www.fda.gov/media/155050/download. Accessed August 20, 2022.

119. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med 2022;386(15):1397–408.

120. Administration FaD. Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. Available at: https://www.fda.gov/media/156152/download . Accessed August 20, 2022.

121. Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med 2021;384(8):693–704.

122. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med 2022;386(15):1397–408.

123. Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med 2022. https://doi.org/10.1016/S2213-2600(22)00088-1.

124. Group RC. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
controlled, open-label, platform trial and updated meta-analysis. Lancet 2022;400(10349):359–68.

125. Guimaraes PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with covid-19 pneumonia. N Engl J Med 2021;385(5):406–15.

126. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397(10285):1637–45.

127. Investigators R-C, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med Apr 22 2021;384(16):1491–502.

128. WHO. Interim statement on COVID-19 vaccination for children. Available at: https://www.who.int/news/item/11-08-2022-interim-statement-on-covid-19-vaccination-for-children. Accessed 8 20, 2022.

129. Infectious Diseases CO. COVID-19 vaccines in infants, children, and adolescents. Pediatrics 2022. https://doi.org/10.1542/peds.2022-058700.

130. Fleming-Dutra KE, Wallace M, Moulia DL, et al. Interim recommendations of the advisory committee on immunization Practices for use of Moderna and pfizer-BioNTech COVID-19 vaccines in children aged 6 Months-5 Years - United States, June 2022. MMWR Morb Mortal Wkly Rep 2022;71(26):859–68.

131. Young-Xu Y, Epstein L, Marconi VC, et al. Tixagevimab/cilgavimab for prevention of COVID-19 during the omicron surge: retrospective analysis of national VA electronic data. medRxiv 2022. https://doi.org/10.1101/2022.05.28.22275716.

132. Al Jurdi A, Morena L, Cote M, et al. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Am J Transplant 2022. https://doi.org/10.1111/ajt.17128.

133. Laboratory-confirmed COVID-19-associated hospitalizations. Centers for disease control and prevention. Available at: https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html. Accessed June 28, 2022.

134. The COVKID project women’s institute for independent social enquiry. Available at: https://www.covkidproject.org. Accessed June 29, 2022.